First-line treatment with modified FOLFOXIRI plus bevacizumab in patients with locally advanced colorectal cancer

Introduction: The combination regimen of fluorouracil, folinate, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bmab) is recommended as the first-line treatment for patients with mutant RAS/BRAF or patients with wild RAS/BRAF right-side located, according to the 2019 colorectal cancer guidelines of the Japanese Society of Cancer for Colon and Rectum. However, little is known the practical results for Japanese patients.